AstraZeneca, opens new tab said it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
Chief Executive Pascal Soriot was in Beijing and met with the city's mayor to reveal the investment, along with two licensing deals with Chinese companies, and a joint venture with a third Chinese firm on vaccines, saying they all showed the company's commitment to the world's No. 2 economy.
"This $2.5 billion investment reflects our belief in the world-class life sciences ecosystem in Beijing, the extensive opportunities that exist for collaboration and access to talent, and our continued commitment to China," Soriot said in a statement.
The R&D centre "will partner with the cutting-edge biology and AI science in Beijing and be a critical part of our global efforts to bring innovative medicines to patients worldwide," Soriot said.
The centre in Beijing will be the company's second R&D site in China - a centre in Shanghai opened in 2024 - to match two such centres each that AstraZeneca has in the U.S. and Europe, respectively, a company spokesperson said.
The Chinese government has launched several investigations into AstraZeneca's executives and activities in the country, where the drugmaker has invested billions of dollars to build factories and license experimental drug candidates from Chinese biotech firms.
China accounted for about 12% of group revenue last year. The company, the UK's largest listed company worth 183 billion pounds ($236 billion) on the blue-chip FTSE 100 index, opens new tab, is the largest foreign drugmaker in China.
Soriot has often visited the country in recent years and praised the value of doing business there even when other multinationals complained of challenges or cited geopolitical tensions between China and Western countries as a risk for the pharma industry.
He is due to attend a flagship development conference in Beijing over the coming days where some are expected to meet Chinese President Xi Jinping.
The company put its former China head Leon Wang, who also led its international business as an executive vice president, on administrative leave following his detention by Chinese authorities in October, and overhauled its local management in China.
Soriot said at quarterly results last month that the company still does not know Wang's whereabouts. Its stock was hit hard by news of the probes in October 2024, but shares have since recovered as investors hope the impact could be minor.
A company spokesperson declined on Friday to comment on the status of the investigations.
The licensing agreements announced on Friday were with Chinese firms Harbour BioMed and Syneron Bio, for early-stage experimental medicines. The financial terms were not disclosed.
The deals were the latest of about a dozen AstraZeneca has signed with Chinese firms in the past several years - including on obesity drugs - worth a total of at least $9 billion, according to the company.
It is also launching a joint venture with another firm, BioKangtai, to develop, manufacture and commercialize vaccines for respiratory and other infectious diseases for patients in China and elsewhere. The site, in Beijing, will be the company's first vaccine manufacturing facility in the country.
The company on Friday also announced a partnership with state-run Beijing Cancer Hospital focused on data science and clinical development.
Global oil prices reached a four year high on Monday (9 March), surpassing $...
Global oil prices surpassed $119 a barrel on Monday (9 March, 2026), an almost four year high, as the Middle East conflict rumbled o...
Kyrgyzstan recorded the largest increase in women’s representation in parliament worldwide in 2025, accordin...
U.S. President Donald Trump and UK Prime Minister Keir Starmer spoke by phone on Sunday as tensions between Washin...
Türkiye’s official anti-disinformation agency has issued a statement refuting what it described as onli...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca is acquiring Belgium-based EsoBiotec for $1 billion to expand its cell therapy capabilities, with the deal set to close in the second quarter.
Mojtaba Khamenei, son of the late Ayatollah Ali Khamenei, is a hardline cleric with strong backing from the Islamic Revolutionary Guard Corps. His rise signals continuity in Tehran's anti-Western policies.
Global oil prices surpassed $119 a barrel on Monday (9 March, 2026), an almost four year high, as the Middle East conflict rumbled on.
Trump says the United States "don’t need people that join wars after we’ve already won," targeting his criticism at UK Prime Minister Keir Starmer. Israel continues to fire missles at strategic sites in Iran and Gulf regions report more strikes from Iran.
China has urged Afghanistan and Pakistan to resolve their dispute through dialogue after Chinese envoy Yue Xiaoyong met Afghan Foreign Minister Amir Khan Muttaqi, as fighting between the two neighbours entered its eleventh day.
Iran named Mojtaba Khamenei to succeed his father Ali Khamenei as supreme leader on Monday (9 March), signaling that hardliners remain firmly in charge, as the week-old U.S.-Israeli war with Iran pushed oil above $100 a barrel.
Measles cases across Europe and Central Asia fell sharply in 2025 compared to the previous year but health officials have warned that the risk of fresh outbreaks remains unless vaccination gaps are urgently addressed.
A Florida university has become a new hotspot in a widening U.S. measles outbreak, with health officials confirming multiple infections and hospitalisations.
The World Health Organization has added the Nipah virus to its list of the world’s top 10 priority diseases, alongside COVID-19 and the Zika virus, warning that its epidemic potential highlights the global risk posed by fast-spreading outbreaks.
Belgian authorities are examining suspected cases of infants falling ill after consuming recalled Nestle baby formula, amid warnings that confirmed infections may be underestimated due to limited testing requirements.
Two Nipah infections involving health workers in India have triggered heightened screening across Southeast Asia as authorities move to prevent the high fatality virus from spreading beyond the country.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment